Scott Bembenek ^UDM

Scott Bembenek is the visionary Founder and CEO of Denovicon Therapeutics, leading the charge in revolutionizing drug discovery. With a robust background in Computer-Aided Drug Discovery, AI, Machine Learning, Molecular Modeling, and Biophysics, he has crafted a best-in-class computational drug discovery platform. This platform integrates cutting-edge technologies such as AI, machine learning, generative therapeutic design, and physics-based approaches. Denovicon's focus spans multiple therapeutic areas, with a current emphasis on small-molecule therapeutics targeting DNA damage response (DDR) pathways and immuno-oncology. Scott's leadership is steering Denovicon towards developing first-in-class molecules, selectively targeting PARP1, PARP2, and PARP7 for a diverse range of diseases in oncology, immunology, neuroscience, and cardiovascular fields. Through his expertise, Denovicon Therapeutics is accelerating the design of the next generation of drugs, marking a significant advancement in the field of drug discovery.